1. Search Result
Search Result
Results for "

XDR

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

1

Peptides

2

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W016420
    Fosfomycin sodium
    Maximum Cited Publications
    6 Publications Verification

    MK-0955 sodium

    Bacterial Antibiotic Infection Cancer
    Fosfomycin (MK-0955) sodium is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin sodium shows both in vivo and in vitro activity against a wide range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria .
    Fosfomycin sodium
  • HY-B1075
    Fosfomycin calcium
    Maximum Cited Publications
    6 Publications Verification

    MK-​0955 calcium

    Bacterial Antibiotic Infection Cancer
    Fosfomycin (MK-0955) calcium is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin calcium shows both in vivo and in vitro activity against a wide range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria .
    Fosfomycin calcium
  • HY-B0609
    Fosfomycin tromethamine
    Maximum Cited Publications
    6 Publications Verification

    MK-0955 tromethamine

    Bacterial Antibiotic Infection Cancer
    Fosfomycin (MK-0955) tromethamine is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin tromethamine shows both in vivo and in vitro activity against a wide range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria .
    Fosfomycin tromethamine
  • HY-147017

    GSK286

    Bacterial Infection Inflammation/Immunology
    GSK2556286 (GSK286) is an orally active inhibitor of M. tuberculosis. GSK2556286 inhibits growth within human macrophages (IC50 = 0.07 μM). GSK2556286 is effective against both multidrug-resistant (MDR) or extensively drug-resistant (XDR) and agent-sensitive (DS) M. tuberculosis.
    GSK2556286
  • HY-P5704

    Bacterial Infection
    K11 is an antimicrobial peptide. K11 is active against MDR/XDR K. pneumoniae isolates (MIC: 8-512 μg/mL), and inhibits bacterial biofilm formation. K11 can act synergistically with antibiotics (Chloramphenicol (HY-B0239), Meropenem (HY-13678), Rifampicin (HY-B0272), etc.) against drug-resistant K. pneumoniae. K11 has high thermal and wide pH stability .
    K11
  • HY-149581

    Bacterial Infection
    DprE1-IN-9 (compound B18) is an effective reversible DprE1 inhibitor and can bind to the receptor cavity of DprE1. DprE1-IN-9 shows strong antimycobacterial activity not only against non-pathogenic strain H37Ra (MIC=0.18 µg/mL) but also against pathogenic H37Rv and the clinical MDR and XDR isolates .
    DprE1-IN-9
  • HY-B1075A

    MK-0955

    Bacterial Antibiotic Infection
    Fosfomycin (MK-0955) is a broad-spectrum antibiotic. Fosfomycin can cross blood-brain barrier penetrating, and irreversibly inhibits an early stage in cell wall synthesis. Fosfomycin shows anti-bacteria activity for a range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria .
    Fosfomycin
  • HY-B1075R

    Bacterial Antibiotic Infection Cancer
    Fosfomycin (calcium) (Standard) is the analytical standard of Fosfomycin (calcium). This product is intended for research and analytical applications. Fosfomycin (MK-0955) calcium is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin calcium shows both in vivo and in vitro activity against a wide range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria .
    Fosfomycin calcium (Standard)
  • HY-N8388

    Bacterial Infection
    Collinin is a anti-tubercular agent, it can be isolated from leaves of Z. schinifolium. Collinin has an excellent anti-tuberculosis effect against multidrug-resistant (MDR), extensively drug-resistant (XDR) strains .
    Collinin
  • HY-B1075AS

    MK-0955 (benzylamine)-13C3

    Bacterial Antibiotic Infection
    (Rac)-Fosfomycin (benzylamine)- 13C3 is the 13C labeled Fosfomycin[1]. Fosfomycin (MK-0955) is a broad-spectrum antibiotic. Fosfomycin can cross blood-brain barrier penetrating, and irreversibly inhibits an early stage in cell wall synthesis. Fosfomycin shows anti-bacteria activity for a range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria[2][3].
    (Rac)-Fosfomycin (benzylamine)-13C3
  • HY-111521

    Carbavance

    Others Infection
    Meropenem-vaborbactam is an antibiotic against nonfermenting Gram-negative clinical isolates, including Enterobacteriaceae isolates with resistant and carbapenemase genotypes. The susceptibility of Meropenem-vaborbactam (at an inhibitory concentration of 8 μg/ml) and comparators was tested against 14,304 nonfermenting Gram-negative clinical isolates collected worldwide in 2014 by reference broth microdilution. Carbapenemase-encoding genes were screened by PCR and sequencing. At concentrations of ≤1 and ≤2 μg/ml, Meropenem-vaborbactam inhibited 99.1 and 99.3% of the 10,426 Enterobacteriaceae isolates tested, respectively, while Meropenem inhibited 97.3 and 97.7% of these isolates at the same concentrations. For isolates displaying carbapenem-resistant Enterobacteriaceae (CRE) (n = 265), multiagent-resistant (MDR) (n = 1,210), and extensively agent-resistant (XDR) (n = 161) phenotypes, meropenem-vaborbactam had MIC50/90 values of 0.5/32, 0.03/1, and 0.5/32 μg/ml, respectively, while meropenem activity was 16/>32, 0.06/32, and 0.5/32 μg/ml, respectively. Among all geographic regions, activity was highest in the United States against CRE and MDR isolates (MIC50/90, 0.03/1 and 0.03/0.12 μg/ml, respectively). Meropenem-vaborbactam was highly active against 135 KPC-producing isolates, with all isolates inhibited at concentrations ≤8 μg/ml (133 isolates were inhibited at concentrations ≤2 μg/ml). The combination had limited activity against isolates producing metallo-β-lactamases (including 25 NDM-1 and 16 VIM producers) and/or oxocephalosporinases (27 OXA-48/OXA-163 producers), which were mainly found in the Asia-Pacific region and some European countries. Meropenem-vaborbactam had activity comparable to meropenem against Pseudomonas spp., Acinetobacter spp., and Clostridium amylovora. Meropenem-vaborbactam was active against a global collection of contemporary Enterobacteriaceae isolates, and the combination had greater activity against CRE isolates and KPC producers than did meropenem and most comparators, which are often multiagent-resistant.
    Meropenem-vaborbactam

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: